Every 8-K that Cel-Sci Corporation (CVM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVM filings page.
CEL-SCI Corporation held its annual shareholder meeting on August 14, 2026, where shareholders elected three directors for the upcoming year. Geert Kersten received 4,371,909 votes for and 478,675 withheld; Bruno Baillavoine received 2,188,254 for and 2,662,330 withheld; Robert Watson received 2,062,150 for and 2,788,434 withheld, with 4,365,596 broker non-votes for each director.
Shareholders approved CEL-SCI’s 2026 Non-Qualified Stock Option Plan, 2026 Stock Bonus Plan, a non-binding advisory vote on executive compensation, and ratified BDO USA, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026. For these proposals, votes for ranged from 3,654,395 to 8,638,163. On the advisory vote regarding the frequency of say-on-pay, shareholders cast 1,692,789 votes for one year, 158,296 for two years, and 2,668,661 for three years, with 330,838 abstentions.
CEL-SCI Corporation has priced a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, for expected gross proceeds of $2.5 million before fees and expenses. The offering is expected to close on June 16, 2026, subject to customary conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. The shares are being sold under an effective Form S-3 shelf registration, with ThinkEquity acting as sole placement agent.
CEL-SCI Corporation has signed a strategic partnership with Amarox to register, commercialize, and distribute its investigational cancer immunotherapy Multikine for head and neck cancer in Saudi Arabia, with an option to expand into Gulf Cooperation Council countries.
Amarox will lead all Saudi Food and Drug Authority regulatory activities, including seeking Breakthrough Medicine Designation, and will become the exclusive distributor in Saudi Arabia if SFDA approval is granted. Net revenue from Multikine sales in Saudi Arabia will be shared equally on a 50%/50% basis, while CEL-SCI keeps global intellectual property and manufacturing rights. The deal targets a fast-growing Saudi cancer immunotherapy market projected to reach $2.7 billion by 2033 and aligns with Saudi Arabia’s Vision 2030 health initiatives.
CEL-SCI Corporation priced a best-efforts public offering of 6,000,000 shares of common stock at $1.20 per share, for expected gross proceeds of about $7.2 million before fees and expenses. The offering is expected to close on May 13, 2026, subject to customary closing conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. Multikine has been dosed in over 740 patients and has received FDA Orphan Drug designation for neoadjuvant treatment of head and neck cancer, but it is not yet approved for sale.
CEL-SCI Corporation filed a Form 8-K to report that its Board of Directors approved revisions to the company’s Shareholder Rights Agreement on November 18, 2025. This type of agreement generally defines how holders of the company’s common stock are protected and what rights are attached to their shares. The revised Shareholder Rights Agreement is included as Exhibit 4, described as an instrument defining the rights of security holders.
CEL-SCI Corporation amended its Shareholder Rights Agreement, setting a new expiration of October 30, 2030. The agreement was originally adopted on November 7, 2007. The company filed the amended agreement as an exhibit and referenced the summary in its prior Form S-3 under “Description of Securities - Rights Agreement.”
CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC for a registered direct offering of 1,111,200 shares of common stock at $9.00 per share. The offering closed on August 29, 2025, generating gross proceeds of approximately $10,000,800 before fees and expenses. CEL-SCI plans to use the net proceeds to continue developing its Multikine program, as well as for general corporate purposes and working capital.
The company will pay the placement agent a 7.0% cash fee on gross proceeds and reimburse certain expenses up to $185,000. For 30 days after closing, CEL-SCI agreed not to issue or register additional equity securities, subject to exceptions, and its directors and officers agreed to 45-day lock-ups on sales or transfers of company securities. The shares were sold under an effective Form S-3 shelf registration and related prospectus supplement.